Drug intelligence / Profile preview

WHP Omega 3

Development stage
Unknown
Lead developer
Homeosyn Italia
Modality
Small Molecules
Administration
Oral
01

Overview

WHP Omega 3 is a nutraceutical dietary supplement developed by Homeosyn Italia, formulated as oral softgels (perles). It contains a 72.4% concentration of fish oil, providing a 50% concentration of the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The product is indicated for the management of dyslipidemia and lipid metabolism disorders due to its ability to lower cholesterol and normalize triglyceride levels. Its mechanism involves the activation of prostaglandins and acting as a natural antioxidant. It is also utilized as an adjuvant in antihypertensive therapy and is marketed through pharmacies in Italy.

Brand names
WHP Omega 3WHP OMEGA-3 30 Perle
Other names
omega-3 supplementomega3 supplementomega 3 supplement
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)PPARD (Peroxisome proliferator–activated receptor delta)

Beyond the preview

Go deeper on WHP Omega 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WHP Omega 3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call